FindTrial
Sign In

To study the improvement in symptoms and quality of life in patients with severe form of asthma after prescribing them a medication called extra-fine beclomethasone which reached right to the small airways

Treatment outcomes with extra-fine beclomethasone-formoterol in patients with uncontrolled asthma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062844
Enrollment
150
Registered
2024-02-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J989- Respiratory disorder, unspecified

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

Cipla Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria 1.Male and female participants more than equal to 18 years of age 2.Asthma patients uncontrolled on ICS LABA combination 3.Have been prescribed Niveoli for the very first time.

Exclusion criteria

Exclusion criteria: Exclusion criteria 1.Participants below the age of 18 years 2.Participants unable to perform spirometry or and lung oscillometry. 3.Participants not willing to provide consent to participate.

Design outcomes

Primary

MeasureTime frame
•Symptoms •Quality of life •Asthma control •Lung function test (Spirometry,Lung Oscillometer and PEFR if available) •Exacerbations and current medicationsTimepoint: Baseline, 3month, 6month—

Secondary

MeasureTime frame
•Symptoms •Quality of life •Asthma control •Lung function test (Spirometry,Lung Oscillometer and PEFR if available) •Exacerbations and current medicationsTimepoint: Baseline, 3month, 6month—

Countries

India

Contacts

Public ContactDeesha Ghorpade

Chest Research and Training Pvt Ltd

deesha.ghorpade@yahoo.in09604643295

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026